Cerebrospinal Fluid Somatostatin and Neuropeptide Y: Concentrations in Aging and in Dementia of the Alzheimer Type With and Without Extrapyramidal Signs

John R. Atack, M. Flint Beal, Conrad May, Jeffrey Kaye, Michael F. Mazurek, Arthur D. Kay, Stanley I. Rapoport

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Cerebrospinal fluid somatostatin and neuropeptide Y concentrations were measured in 26 healthy normal subjects, 27 patients with dementia of the Alzheimer type (DAT), and seven patients with DAT with extrapyramidal signs (EDAT). In healthy normal subjects, there was no significant correlation between age and either somatostatin or neuropeptide Y concentration. However, the concentrations of both peptides correlated significantly with each other. In patients with DAT and EDAT, the concentrations of somatostatin (17.5 ± 5.0 and 16.4 ± 5.0 pg/mL, respectively) were significantly reduced relative to age-matched control subjects (23.1 ± 8.2 pg/mL) but were unrelated to dementia severity and did not change significantly during the progression of the disease. Neuropeptide Y concentrations did not differ significantly between the age-matched control, DAT, and EDAT groups (38.2 ± 12.8, 37.0 ± 12.3, and 30.3 ± 7.8 pg/mL, respectively). These results suggest that in DAT, dysfunction of cortical somatostatin but not neuropeptide Y transmitter systems is reflected by reduced cerebrospinal fluid concentrations.

Original languageEnglish (US)
Pages (from-to)269-274
Number of pages6
JournalArchives of Neurology
Volume45
Issue number3
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Neuropeptide Y
Somatostatin
Cerebrospinal Fluid
Alzheimer Disease
Healthy Volunteers
Dementia
Disease Progression
Alzheimer
Peptides

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cerebrospinal Fluid Somatostatin and Neuropeptide Y : Concentrations in Aging and in Dementia of the Alzheimer Type With and Without Extrapyramidal Signs. / Atack, John R.; Beal, M. Flint; May, Conrad; Kaye, Jeffrey; Mazurek, Michael F.; Kay, Arthur D.; Rapoport, Stanley I.

In: Archives of Neurology, Vol. 45, No. 3, 1988, p. 269-274.

Research output: Contribution to journalArticle

Atack, John R. ; Beal, M. Flint ; May, Conrad ; Kaye, Jeffrey ; Mazurek, Michael F. ; Kay, Arthur D. ; Rapoport, Stanley I. / Cerebrospinal Fluid Somatostatin and Neuropeptide Y : Concentrations in Aging and in Dementia of the Alzheimer Type With and Without Extrapyramidal Signs. In: Archives of Neurology. 1988 ; Vol. 45, No. 3. pp. 269-274.
@article{4669ab45bcfb4242ac618d4308455b96,
title = "Cerebrospinal Fluid Somatostatin and Neuropeptide Y: Concentrations in Aging and in Dementia of the Alzheimer Type With and Without Extrapyramidal Signs",
abstract = "Cerebrospinal fluid somatostatin and neuropeptide Y concentrations were measured in 26 healthy normal subjects, 27 patients with dementia of the Alzheimer type (DAT), and seven patients with DAT with extrapyramidal signs (EDAT). In healthy normal subjects, there was no significant correlation between age and either somatostatin or neuropeptide Y concentration. However, the concentrations of both peptides correlated significantly with each other. In patients with DAT and EDAT, the concentrations of somatostatin (17.5 ± 5.0 and 16.4 ± 5.0 pg/mL, respectively) were significantly reduced relative to age-matched control subjects (23.1 ± 8.2 pg/mL) but were unrelated to dementia severity and did not change significantly during the progression of the disease. Neuropeptide Y concentrations did not differ significantly between the age-matched control, DAT, and EDAT groups (38.2 ± 12.8, 37.0 ± 12.3, and 30.3 ± 7.8 pg/mL, respectively). These results suggest that in DAT, dysfunction of cortical somatostatin but not neuropeptide Y transmitter systems is reflected by reduced cerebrospinal fluid concentrations.",
author = "Atack, {John R.} and Beal, {M. Flint} and Conrad May and Jeffrey Kaye and Mazurek, {Michael F.} and Kay, {Arthur D.} and Rapoport, {Stanley I.}",
year = "1988",
doi = "10.1001/archneur.1988.00520270043019",
language = "English (US)",
volume = "45",
pages = "269--274",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Cerebrospinal Fluid Somatostatin and Neuropeptide Y

T2 - Concentrations in Aging and in Dementia of the Alzheimer Type With and Without Extrapyramidal Signs

AU - Atack, John R.

AU - Beal, M. Flint

AU - May, Conrad

AU - Kaye, Jeffrey

AU - Mazurek, Michael F.

AU - Kay, Arthur D.

AU - Rapoport, Stanley I.

PY - 1988

Y1 - 1988

N2 - Cerebrospinal fluid somatostatin and neuropeptide Y concentrations were measured in 26 healthy normal subjects, 27 patients with dementia of the Alzheimer type (DAT), and seven patients with DAT with extrapyramidal signs (EDAT). In healthy normal subjects, there was no significant correlation between age and either somatostatin or neuropeptide Y concentration. However, the concentrations of both peptides correlated significantly with each other. In patients with DAT and EDAT, the concentrations of somatostatin (17.5 ± 5.0 and 16.4 ± 5.0 pg/mL, respectively) were significantly reduced relative to age-matched control subjects (23.1 ± 8.2 pg/mL) but were unrelated to dementia severity and did not change significantly during the progression of the disease. Neuropeptide Y concentrations did not differ significantly between the age-matched control, DAT, and EDAT groups (38.2 ± 12.8, 37.0 ± 12.3, and 30.3 ± 7.8 pg/mL, respectively). These results suggest that in DAT, dysfunction of cortical somatostatin but not neuropeptide Y transmitter systems is reflected by reduced cerebrospinal fluid concentrations.

AB - Cerebrospinal fluid somatostatin and neuropeptide Y concentrations were measured in 26 healthy normal subjects, 27 patients with dementia of the Alzheimer type (DAT), and seven patients with DAT with extrapyramidal signs (EDAT). In healthy normal subjects, there was no significant correlation between age and either somatostatin or neuropeptide Y concentration. However, the concentrations of both peptides correlated significantly with each other. In patients with DAT and EDAT, the concentrations of somatostatin (17.5 ± 5.0 and 16.4 ± 5.0 pg/mL, respectively) were significantly reduced relative to age-matched control subjects (23.1 ± 8.2 pg/mL) but were unrelated to dementia severity and did not change significantly during the progression of the disease. Neuropeptide Y concentrations did not differ significantly between the age-matched control, DAT, and EDAT groups (38.2 ± 12.8, 37.0 ± 12.3, and 30.3 ± 7.8 pg/mL, respectively). These results suggest that in DAT, dysfunction of cortical somatostatin but not neuropeptide Y transmitter systems is reflected by reduced cerebrospinal fluid concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0023911284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023911284&partnerID=8YFLogxK

U2 - 10.1001/archneur.1988.00520270043019

DO - 10.1001/archneur.1988.00520270043019

M3 - Article

C2 - 2893600

AN - SCOPUS:0023911284

VL - 45

SP - 269

EP - 274

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 3

ER -